LifeMD, Inc. (NASDAQ:LFMD) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• LifeMD has an average analyst rating of Moderate Buy from nine brokers (seven buy, one hold, one sell) with an average 1‑year target of $9.14.
• The company missed its most recent quarter—EPS of ($0.04) vs. consensus ($0.01) and revenue $46.87M vs. $48.57M—and reported a negative return on equity of 83.93% despite a 6.58% net margin.
• Shares opened around $5.13 with a market cap of about $244M, a 52‑week range of $2.56–$15.84, 50‑/200‑day moving averages near $3.79/$3.95, and institutions owning 35.52% of the stock.

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) has been given an average rating of "Moderate Buy" by the nine brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $9.1429.

LFMD has been the subject of several research reports. Wall Street Zen raised shares of LifeMD from a "sell" rating to a "hold" rating in a research note on Saturday, March 14th. Weiss Ratings reissued a "sell (e+)" rating on shares of LifeMD in a research note on Friday, March 27th. Cantor Fitzgerald restated an "overweight" rating on shares of LifeMD in a report on Tuesday, March 10th. BTIG Research restated a "buy" rating and issued a $10.00 price target on shares of LifeMD in a research report on Monday. Finally, Mizuho upgraded LifeMD from a "neutral" rating to an "outperform" rating and lifted their price objective for the stock from $6.00 to $8.00 in a research report on Monday, March 16th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd acquired a new position in shares of LifeMD during the 4th quarter valued at about $36,000. Magnus Financial Group LLC acquired a new stake in LifeMD during the fourth quarter worth about $41,000. R Squared Ltd acquired a new stake in LifeMD during the first quarter worth about $41,000. Jain Global LLC purchased a new position in LifeMD during the fourth quarter worth about $45,000. Finally, Quarry LP purchased a new position in LifeMD during the third quarter worth about $52,000. Hedge funds and other institutional investors own 35.52% of the company's stock.

LifeMD Stock Performance

NASDAQ LFMD opened at $5.13 on Wednesday. The business has a fifty day moving average price of $3.79 and a 200 day moving average price of $3.95. The company has a market cap of $244.19 million, a P/E ratio of 19.73 and a beta of 2.03. LifeMD has a one year low of $2.56 and a one year high of $15.84.

LifeMD (NASDAQ:LFMD - Get Free Report) last released its earnings results on Monday, March 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.03). The business had revenue of $46.87 million for the quarter, compared to analysts' expectations of $48.57 million. LifeMD had a negative return on equity of 83.93% and a net margin of 6.58%. As a group, sell-side analysts predict that LifeMD will post 0.01 EPS for the current fiscal year.

LifeMD Company Profile

LifeMD NASDAQ: LFMD is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.